- Full Time Employees
- 534
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Seoul South Korea
- IPO Date
- Sep 29, 2022
- Business
- RPbio Inc. is a South Korea-based pharmaceutical and nutritional healthcare company that specializes in the research, development, contract development and manufacturing (CDMO), original equipment manufacturing (OEM), and original design manufacturing (ODM) of soft gelatin capsules, health functional foods, and specialty oral dosage forms. Founded in 1983 as RP Scherer Korea, a joint venture between Daewoong Pharmaceutical Co., Ltd. and R.P. Scherer Corporation, the company is headquartered in Seoul, South Korea, and operates advanced production and research facilities in Hyangnam and Mado, Gyeonggi Province. RPbio Inc. is listed on the Korea Exchange under the ticker symbol KRX:314140 and serves domestic and international pharmaceutical firms, healthcare enterprises, and consumer health brand owners, including Daewoong Pharmaceutical, Chong Kun Dang, and Yuhan Corporation.
The company's core operations are structured into two principal business divisions: Pharmaceuticals and Health Functional Foods. RPbio Inc. manufactures and supplies a comprehensive portfolio of products and formulation technologies, including: over-the-counter (OTC) and prescription pharmaceuticals, comprising cold and flu remedies, antipyretic analgesics, nonsteroidal anti-inflammatory drugs, hepatoprotective and liver support agents, cardiovascular and circulatory regulators, and therapeutic vitamin compounds; health functional food supplements, comprising omega-3 fish oil, lutein and zeaxanthin eye health formulations, coenzyme Q10, customized multivitamin complexes, minerals, and dietary health nutrients; specialized oral delivery dosage forms, comprising traditional soft gelatin capsules, plant-based vegetarian soft capsules, enteric-coated soft capsules, chewable capsules, and dual-formulation liquid-gel complexes; and proprietary formulation platforms, comprising Neosol and New Neosol solubility enhancement technology for improving the bioavailability and dissolution rates of hydrophobic active pharmaceutical ingredients, Neogel and New Neogel shell stability technology designed to prevent capsule leakage, hardening, and degradation over extended shelf lives, and sustained-release encapsulation systems.
In recent operational developments, RPbio Inc. has accelerated its global CDMO expansion and diversified its formulation portfolio. The company developed and commercialized Blister Jelly and Boost Jelly, an innovative oral dosage format utilizing automated direct-fill aluminum-aluminum (Alu-Alu) blister packaging technology to prevent oxidation, maintain active ingredient integrity, and address consumer demand for functional confectionery-style supplements. To support rising domestic and international order volumes, the company completed a substantial manufacturing capacity expansion at its Mado facility, increasing production output by more than 70 percent. Internationally, RPbio Inc. successfully completed a United States Food and Drug Administration (FDA) current Good Manufacturing Practice (cGMP) site inspection with Voluntary Action Indicated (VAI) status, secured international FSSC 22000 food safety system certification, and obtained United Kingdom FAPAS proficiency verification to advance direct contract manufacturing exports across North America and the Asia-Pacific region. Strategically, the company launched an enterprise-wide digital transformation (DX) initiative to implement smart manufacturing systems and completed executive leadership realignments under Chief Executive Officer Yoon Jae-hoon to reinforce corporate governance and commercial execution.